Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Survival and desferrioxamine in thalassaemia major.

Literature DB >> 6802413

Survival and desferrioxamine in thalassaemia major.

B Modell, E A Letsky, D M Flynn, R Peto, D J Weatherall.

Abstract

A small randomised trial and observation of all patients homozygous for beta-thalassaemia in Britain born in or before 1963 indicated that those patients who had received average weekly doses of more than 4 g of desferrioxamine over the previous few years were less likely to die in the near future than were patients of similar ages who had received less, or no, desferrioxamine.

Entities: Chemical Disease Species

Mesh：

Substances：
Deferoxamine

Year: 1982 PMID： 6802413 PMCID： PMC1497956 DOI： 10.1136/bmj.284.6322.1081

Source DB: PubMed Journal: Br Med J (Clin Res Ed) ISSN： 0267-0623

14 in total

1. A controlled trial of long-term chelation therapy in homozygous beta-thalassemia.

Authors: E A Letsky
Journal: Birth Defects Orig Artic Ser Date: 1976

2. Continuous subcutaenous administration of deferoxamine in patients with iron overload.

Authors: R D Propper; B Cooper; R R Rufo; A W Nienhuis; W F Anderson; H F Bunn; A Rosenthal; D G Nathan
Journal: N Engl J Med Date: 1977-08-25 Impact factor: 91.245

3. Long-term desferrioxamine therapy in thalassemia.

Authors: C B Modell; J Beck
Journal: Ann N Y Acad Sci Date: 1974 Impact factor: 5.691

4. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload.

Authors: M A Hussain; N Green; D M Flynn; S Hussein; A V Hoffbrand
Journal: Lancet Date: 1976-12-11 Impact factor: 79.321

5. Cardiac arrhythmias in thalassaemia major: evaluation of chelation treatment using ambulatory monitoring.

Authors: S B Kaye; M Owen
Journal: Br Med J Date: 1978-02-11

6. Echocardiographic abnormalities in patients with transfusion-dependent anemia and secondary myocardial iron deposition.

Authors: W L Henry; A W Nienhuis; M Wiener; D R Miller; V C Canale; S Piomelli
Journal: Am J Med Date: 1978-04 Impact factor: 4.965

7. Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress.

Authors: M Barry; D M Flynn; E A Letsky; R A Risdon
Journal: Br Med J Date: 1974-04-06

8. Reassessment of the use of desferrioxamine B in iron overload.

Authors: R D Propper; S B Shurin; D G Nathan
Journal: N Engl J Med Date: 1976-06-24 Impact factor: 91.245

9. Prevention of iron loading in transfusion-dependent thalassaemia.

Authors: M J Pippard; E A Letsky; S T Callender; D J Weatherall
Journal: Lancet Date: 1978-06-03 Impact factor: 79.321

10. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors: R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal: Br J Cancer Date: 1977-01 Impact factor: 7.640

27 in total

Survival and desferrioxamine in thalassaemia major.

1. A controlled trial of long-term chelation therapy in homozygous beta-thalassemia.

2. Continuous subcutaenous administration of deferoxamine in patients with iron overload.

3. Long-term desferrioxamine therapy in thalassemia.

4. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload.

5. Cardiac arrhythmias in thalassaemia major: evaluation of chelation treatment using ambulatory monitoring.

6. Echocardiographic abnormalities in patients with transfusion-dependent anemia and secondary myocardial iron deposition.

7. Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress.

8. Reassessment of the use of desferrioxamine B in iron overload.

9. Prevention of iron loading in transfusion-dependent thalassaemia.

10. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Review 1. Bone marrow transplantation for thalassaemia major.

2. Oral iron chelating drugs: coming but not yet ready for clinical use.

Review 3. Prospects for the use of antioxidant therapies.

4. Management of thalassaemia major.

Review 5. Oxygen toxicity, oxygen radicals, transition metals and disease.

6. Community control of hereditary anaemias: memorandum from a WHO meeting.

7. Early iron overload in beta-thalassaemia major: when to start chelation therapy?

Review 8. Iron-chelating therapy for transfusional iron overload.

9. Thalassemia in Bombay: the role of medical genetics in developing countries.

10. Evaluation of growth hormone in thalassaemic boys with failed puberty: spontaneous versus provocative test.